Tenax Therapeutics, INC. (TENX) — DEF 14A Filings

All DEF 14A filings from Tenax Therapeutics, INC.. Browse 3 Proxy Statement reports with AI-powered summaries and risk analysis.

DEF 14A Filings (3)

Tenax Therapeutics Executive Compensation Details Revealed — Apr 25, 2025 Risk: medium
Tenax Therapeutics, Inc. filed its DEF 14A on April 25, 2025, detailing executive compensation and stock awards for the fiscal years ending December 31, 2022, 2
Tenax Therapeutics Files Proxy Statement for Annual Meeting — Sep 27, 2024 Risk: low
Tenax Therapeutics, Inc. filed its definitive proxy statement on September 27, 2024, for its annual meeting of stockholders. The filing outlines the proposals t
Tenax Therapeutics, Inc. Announces Annual Meeting of Stockholders on June 7, 2024 — Apr 26, 2024 Risk: low
TENAX THERAPEUTICS, INC. (TENX) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. The Annual Meeting of Stockholders for Tenax Therapeutics, Inc

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX